Pyruvate kinase activators for use in treating blood disorders
US-11364240-B2 · Jun 21, 2022 · US
Pyruvate kinase activators for use in treating blood disorders
US11957680B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11957680-B2 |
| Application number | US-202217744806-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 16, 2022 |
| Priority date | Aug 15, 2017 |
| Publication date | Apr 16, 2024 |
| Grant date | Apr 16, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R 1 , R 2 , L 1 , and L 2 are as defined herein.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound having a structural formula selected from: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is of the structural formula: 3. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical composition comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof. 5. A method for treating a condition selected from sickle cell disease, pyruvate kinase deficiency (PKD), and thalassemia in a subject comprising administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof. 6. A method for treating a condition selected from sickle cell disease, pyruvate kinase deficiency (PKD), and thalassemia in a subject comprising administering to the subject an effective amount of the compound according to claim 2 , or a pharmaceutically acceptable salt thereof. 7. The method of claim 5 , wherein the condition is sickle cell disease. 8. The method of claim 5 , wherein the condition is pyruvate kinase deficiency (PKD). 9. The method of claim 5 , wherein the condition is thalassemia. 10. The method of claim 6 , wherein the condition is sickle cell disease. 11. The method of claim 6 , wherein the condition is pyruvate kinase deficiency (PKD). 12. The method of claim 6 , wherein the condition is thalassemia. 13. A method of treating hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia or Bassen-Kornzweig syndrome, sickle cell disease, paroxysmal nocturnal hemoglobinuria, anemia, hemolytic anemia, acquired hemolytic anemia, or anemia of chronic diseases in a subject in need thereof, a method of increasing amount of hemoglobin in a subject in need thereof, a method of increasing the lifetime of red blood cells (RBCs) in a subject in need thereof, a method for regulating 2,3-diphosphoglycerate levels in blood in a subject in need thereof, or a method for activating pyruvate kinase R (PKR) in red blood cells in a subject in need thereof, comprising administering to a subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof. 14. A method of treating hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia or Bassen-Kornzweig syndrome, sickle cell disease, paroxysmal nocturnal hemoglobinuria, anemia, hemolytic anemia, acquired hemolytic anemia, or anemia of chronic diseases in a subject in need thereof, a method of increasing amount of hemoglobin in a subject in need thereof, a method of increasing the lifetime of red blood cells (RBCs) in a subject in need thereof, a method for regulating 2,3-diphosphoglycerate levels in blood in a subject in need thereof, or a method for activating pyruvate kinase R (PKR) in red blood cells in a subject in need thereof, comprising administering to a subject an effective amount of the compound according to claim 2 or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
- A61K31/5025Primary
ortho- or peri-condensed with heterocyclic ring systems · CPC title
not condensed and containing further heterocyclic rings · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
condensed with carbocyclic rings or ring systems · CPC title
- C07D513/14Primary
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11957680B2 cover?
- Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R 1 , R 2 , L 1 , and L 2 are as defined herein.
- Who is the assignee on this patent?
- Agios Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5025. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).